Rebuttal to Mark Farmer National Academies Corrupt
Posted in the Athens Forum
#1 Mar 23, 2014
Corruption of the National Academy of Science, the NIH, NCI and others by
Winfield J. Abbe, Ph.D., October 18, 2011 Partial rebuttal to comments by professor Mark Farmer, Athens Banner Herald Tuesday October 18, 2011 criticizing earlier comments of Neal Boortz.
•“Richard Feynman became so exasperated [at the National Academy of Sciences] that he resigned his membership, saying that he saw no point in belonging to an organization that spent most of its time deciding who to let in.
o Gregory Benford, in "A Scientist's Notebook: Scientist Heroes" in The Magazine of Science Fiction and Fantasy (4/1996)”
o Above statement quoted from http://en.wikiquote.org/wiki/Richard_Feynman .
o Richard Feynman, Ph.D., Richard Chace Tolman Professor of Theoretical Physics at the California Institute of Technology until his death(1918-1988), Nobel Prize in physics 1965 shared with Schwinger and Tomonaga.
“The first principle is that you must not fool yourself, and you are the easiest person to fool.”, Richard Feynman, Ph.D.
“Cancer and Vitamin C” by Ewan Cameron and Linus Pauling, Camino Books, Philadelphia, 1979, 1993.
Page xviii:“The Food and Nutrition Board states that the values of the RDA that the Board has set are large enough so that very few people receiving these amounts would suffer from the corresponding deficiency diseases-scurvy for vitamin C, beriberi for vitamin B1, pellagra for vitamin B3, and so on. The Food and Nutrition Board, however, shows a bias against vitamins and other nutrients similar to that of the writers of the books on health published by the National Academy of Sciences-essentially a rejection of possible value of intakes larger than the RDA’s….”
Current recommended intakes of vitamin C are dismally low: http://www.iom.edu/Activities/Nutrition/Summa...
Linus Pauling, Ph.D., distinguished professor of chemistry at the California Institute of Technology from about 1927 until his technical “retirement” in the 1960’s, is the only person in the world to have received two solo Nobel prizes, chemistry, 1954 and peace, 1962.
“The Cancer Industry Unravelling the Politics” by Ralph W. Moss, Ph.D., Paragon House, NY, 1989:
“The Revelations in this book about the ways in which the American People have been betrayed by the cancer establishment, the medical profession, and the government are shocking. Everyone should know that the ‘war on cancer’ is largely a fraud, and that the National Cancer Institute and the American Cancer Society are derelict in their duties to the people who support them”. Linus Pauling, Ph.D., two time solo Nobel prize winner,(1901-1994).
The author Ralph W. Moss from New York, of the above seminal book, 500 pages with 500 references, who holds a Ph.D. degree in classics from Stanford University in California, was fired as Assistant Director of Public Affairs from Memorial Sloan Kettering Cancer Center in New York in the 1970’s for refusing to lie to the public about scientific research on Laetrile. This book and its successor in 1996 and earlier versions document the dismal corruption of the NIH, NCI and American Cancer Society in the failed war on cancer for decades. For example, it also includes the horror story of the “Summerlin Painted Mouse Affair” describing fraud by a medical doctor at Memorial Sloan Kettering Cancer Center in New York who painted spots on the backs of laboratory animals in order to fool the public and other researchers about cancer research being performed there in the 1970’s; fraud and corruption is nothing new in our government funded laboratories.
#2 Mar 23, 2014
Continued from above:
The following statement and references are quoted from http://www.hydrazinesulfate.org/index.html
“The Truth about hydrazine sulfate- Dr. Gold Speaks” by Joseph Gold, M.D. a distinguished medical doctor and cancer researcher. This article documents how government institutes deliberately and negligently and criminally posted false statements on a government website. Dr. Gold did post graduate work at UC Berkeley many years ago in the 1950’s. The above document is supported by the following 78 references.
“Joseph Gold, M.D., is director of the Syracuse Cancer Research Institute and the developer of hydrazine sulfate as an anticancer drug.
ADDENDUM. It has come to the attention of the Syracuse Cancer Research Institute that the National Cancer Institute has placed the following misrepresentations on the Internet on June 18, 2004, repeated verbatim on March 3, 2005 ( http://www.nci.nih.gov/cancertopics/pdq/cam/h... ), in regard to hydrazine sulfate:
(1)“There is only limited evidence from animal studies that hydrazine sulfate has anticancer activity.”
(2)“Hydrazine sulfate has shown no anticancer activity in randomized clinical trials.”
The first sentence implies there have been no human studies that have demonstrated the anticancer activity of hydrazine sulfate. But, as NCI well knows, there have been many controlled human studies demonstrating the anticancer activity of hydrazine sulfate, dating from as far back as 1975 and published in leading peer-reviewed cancer journals which circulate worldwide (cited in references 15, 17, 23, 27, 29, 34, 35, 41, 78).
The second sentence states categorically there have been no randomized clinical trials demonstrating the anticancer activity of hydrazine sulfate. RCTs represent the “gold standard” of clinical trials, in that they are prospectively randomized, placebo-controlled, double-blind and thus tend to minimize study bias from all sources. But NCI knows there have been four such randomized clinical trials demonstrating the anticancer activity of hydrazine sulfate (references 27, 34, 35, 41), all of which NCI has been aware from the very beginning.
NCI knows that the above statements it has currently placed on the Internet are simply not true.”
1. Gold, J. Proposed treatment of cancer by inhibition of gluconeogenesis. Oncology 22:185-207, 1968.
2. Gold, J. Inhibition of Walker 256 intramuscular carcinoma in rats by administration of hydrazine sulfate. Oncology 25:66-7l, 1971.
3. Gold, J. Cancer cachexia and gluconeogenesis. Ann. N.Y. Acad. Sci. 230:103-110, 1974.
4. Gold, J. Inhibition by hydrazine sulfate and various hydrazides of in-vivo growth of Walker 256 intramuscular carcinoma, B-16 melanoma, Murphy-Sturm lymphosarcoma and L-1210 solid leukemia. Oncology 27:69-80, 1976.
5. Dilman, V.H., Anisomov, V.N., Kolosov, A.I. and Bulovskaya, L.N. On the relationship between the activity of acetylations, growth of experimental tumors and efficacy of their suppression by hydrazine sulfate. Oncology 33:219-221, 1976.
6. Grubbs, B., Rogers W. and Cameron, I. Total parenteral nutrition and inhibition of gluconeogenesis on tumor-host responses. Oncology 36:216-223, 1979.
7. Gold, J. Enhancement by hydrazine sulfate of antitumor effectiveness of Cytoxan, Mitomycin C, Methotrexate and Bleomycin, in Walker 256 carcinosarcoma in rats. Oncology 31:44-53, 1975.
8. Tretyakov, A.V. and Filov, V.A. The mechanism of potentiation by hydrazine sulfate of action of antitumoral compounds. Vopr. Onkol. 23:94-98, 1977.
#3 Mar 23, 2014
9. Gold, J. Potentiation by Clofibrate of in-vivo tumor inhibition by hydrazine sulfate and cytotoxic agents, in Walker 256 carcinosarcoma. Cancer Biochem. Biophys. 3:41-45, 1978.
10. Gold, J. Hydrazine sulfate and cancer cachexia. Nutr. Cancer 1:4-9, 1979.
11. Gold, J. Inhibition of gluconeogenesis at the phosphoenolpyruvate carboxykinase level, as a means of cancer chemotherapy. Proc. Am. Assoc. Cancer Res. 14:9, 1973.
12. Gold, J. Inhibition of gluconeogenesis at the phosphoenolpyruvate carboxykinase and pyruvate carboxylase reactions, as a means of cancer chemotherapy. Oncology 29:74-89, 1974.
13. Hanley, J.M. Letter to the director of the National Cancer Institute, March 8, 1976 .
14. Schonfeld, R.G. Letter to Congressman James M. Hanley, March 19, 1976.
15. Seits, J.F., Gershanovich, M.L., Filov, V.A., et al. Experimental and clinical data on the antitumor action of hydrazine sulfate. Vopr. Onkol. 21:45-52, 1975.
16. Schonfeld, R.G. Letter to Dr. Joseph Gold, director, Syracuse Cancer Research Institute, Syracuse, New York.
17. Gershanovich, M.L., Danova, L.A., Kondratyev, V.B., et al. Clinical data on the antitumor activity of hydrazine sulfate. Cancer Treat. Rep. 60:933-935, 1976.
18. Gold, J. Use of hydrazine sulfate in terminal and preterminal cancer patients: results of Investigational New Drug (IND) study in 84 evaluable patients. Oncology 32:1-10, 1975.
19. Ochoa, M., Jr., Wittes, R.E. and Krakoff, I.H. Trial of hydrazine sulfate (NSC-l500l4) in patients with cancer. Cancer Chemother. Rep. 58:1151-1154, 1975.
20. American Cancer Society. Unproven methods of cancer management: hydrazine sulfate. Ca—A Cancer Journal for Clinicians 26:108-110, 1976.
21. Gershanovich, M.L. and Filov, V.A. Hydrazine sulfate in late stage cancer: completion of initial clinical trials in 225 evaluable patients. Proc. Am. Assoc. Cancer Res. 20:240, 1979.
22. Horwitz, N. Top Ca groups polarized on Russian cachexia study. Medical Tribune, May 16, 1979 .
23. Gershanovich, M.L., Danova, L.A., Ivin, B.A. and Filov, V.A. Results of clinical study of antitumor action of hydrazine sulfate. Nutr. Cancer 3:7-12, 1981.
24. Spremulli, E., Wampler, G.L. and Regelson, W. Clinical study of hydrazine sulfate in advanced cancer patients. Cancer Chemother. Pharmacol. 3:121-124, 1979.
25. Gold, J. Incompatibility of hydrazine sulfate and pentobarbital in the treatment of tumor bearing animals. Proc. Am. Assoc. Cancer Res. 18:250, 1977.
26. Regelson, W. The ‘grand conspiracy' against the cancer cure. J. Am. Med. Assoc. 243:337-339, 1980.
27. Chlebowski, R.T., Heber, D., Richardson , B. and Block, J.B. Influence of hydrazine sulfate on abnormal carbohydrate metabolism in patients with cancer cachexia. Cancer Res. 33:867-871, 1984.
28. DeVita, V.T., Jr., Hellman, S. and Rosenberg , S.A.(eds.). Cancer, Principles & Practice of Oncology, 2 nd Ed., J. B. Lippincott Co.: Philadelphia , 1985, pp. 2333-2344.
29. Filov, V.A., Ivin, V.A. and Gershanovich, M.L.(eds.). Medical Therapy of Tumors, U.S.S.R. Ministry of Health: Leningrad , l983, pp. 92-139.
30. Chlebowski, R.T., Heber, D., Richardson , B. and Block, J.B. Influence of hydrazine sulfate (HS) on carbohydrate metabolism in cancer cachexia: a randomized, placebo-controlled trial. Proc. Am. Soc. Clin. Oncol. 1:59, 1982.
#4 Mar 23, 2014
31. Chlebowski, R.T., Heber, D., Richardson, B., et al. Association between improved carbohydrate metabolism and weight maintenance in hydrazine sulfate treated patients with cancer cachexia. Proc. Am. Soc. Clin. Oncol. 2:95, 1983.
32. Chlebowski, R.T. Letter to Robert E. Wittes, M.D., Associate Director for Cancer Therapy Evaluation, National Cancer Institute, April 19, 1985.
33. Personal communication, Nackey Scripps Loeb, publisher, The Union Leader, Manchester , New Hampshire .
34. Chlebowski, R.T., Bulcavage, L., Grosvenor, M., et al. Hydrazine sulfate in cancer patients with weight loss: a placebo-controlled experience. Cancer 59:406-410, 1987.
35. Tayek, J.A., Heber, D. and Chlebowski, R.T. Effect of hydrazine sulphate on whole-body protein breakdown measured by14 C-lysine metabolism in lung cancer patients: Lancet 2:241-244, 1987.
36. Chlebowski, R.T., Bulcavage, L., Grosvenor, M., et al. Influence of hydrazine sulfate on survival in non-small-cell lung cancer: a randomized, placebo-controlled trial. Proc. Am. Soc. Clin. Oncol. 6:175, 1987.
37. Rovner, S. For cancer drug, a long road to recognition. The Washington Post, May 17, 1988 .
38. ABC News (telecast). The war on cancer: cure, profit or politics? 20/20 Special Report, October 22, 1981 .
39. Carbone, P.P. Developing a postgraduate medical oncology training program in Taipei, Taiwan, Republic of China. J. Clin. Oncol. 9:335-338, 1991.
40. Personal communication, J. B. Block.
41. Chlebowski, R.T., Bulcavage, L., Grosvenor, M., et al. Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer. J. Clin. Oncol. 8:9-15, 1990.
42. Piantadosi, S. Hazards of small clinical trials. J. Clin. Oncol. 8:1-3, 1990.
43. Gold, J. Hydrazine sulfate in non-small-cell lung cancer. J. Clin. Oncol. 8:1117-1118, 1990.
44. Gilman, A.G., Rall, T.W., Nies, A.S. and Taylor, P.(eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8 th Ed., Pergamon Press:Elmsford, 1990, pp. 416-417.
45. Gold, J. Telephone communication to Dr. Michael Friedman, Associate Director, CTEP, National Cancer Institute, July 25, 1989 .
46. Gold, J. Letter to Dr. Mark Green, CALGB Respiratory Core Chairman, July 31, 1989.
47. Gold, J. Letter to Mary McCabe, Protocol Specialist, Cancer Therapy Evaluation Program, National Cancer Institute, August 23, 1989 .
48. Stukov, A.N., Razumeiko, O.B. and Filov, V.A. On the incompatibility of hydrazine sulfate with ethanol and barbiturates. U.S.S.R. Dep. UISTI (All-Union Institute of Scientific and Technical Information) N 1706-75 Dep., 1975.
49. Filov, V.A., Stukov, A.N., Blan, N.A. and Niestadt, E.L. Experimental data on the toxic effect of hydrazine sulfate on the organism and tumor. Farmakol. Toksikol. 41:203-205, 1978.
50. Kosty, M.P. Letter to Dr. Joseph Gold, September 15, 1989 .
51. Kosty, M.P., Fleishman, S.B., Herndon, J.E., II, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B, J. Clin. Oncol. 12:1113-1120, 1994.
52. Loprinzi, C.L., Kuross , S.A., O'Fallon, J.R., et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J. Clin. Oncol. 12:1121-1125, 1994.
53. Loprinzi, C.L., Goldberg, R.M., Sy, J.Q., et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer: J. Clin. Oncol. 12:1126-1129, 1994.
54. Herbert, V. Three stakes in hydrazine sulfate's heart, but questionable cancer remedies, like vampires, always rise again. J. Clin. Oncol. 12:1107-1108, 1994.
55. Kosty, M.P., Herndon, J.E., II, Green, M.R. and McIntyre, O.R. Placebo-controlled randomized study of hydrazine sulfate in lung cancer. J. Clin. Oncol. 13:1529-1530, 1995.
56. Friedman, M.A. Letter to Dr. Vera A. Gorbunova, September 14, 1994 .
#5 Mar 23, 2014
57. Program, National Cancer Institute Bychkov, M.B. Letter to Dr. Michael A. Friedman, Associate Director, Cancer Therapy Evaluation, October 4, 1994 .
58. Friedman, M.A. Letter to Barry D. Tice, Associate Director, Health Planning Division, U.S. General Accounting Office, June 27, 1995.
59. Personal communication, Barry D. Tice.
60. Schilsky, R.L. Letter to Barry D. Tice, May 30, 1995 .
61. Wilkins, R.D. Critique of CALGB retrospective analyses of hydrazine sulfate study. February 15, 1996 .
62. U.S. General Accounting Office. NIH actions spur continued controversy over hydrazine sulfate therapy. Draft Report, GAO/HEHS-95-141, June 5, 1995.
63. Kamen, J. Intent to kill: the government conspiracy to destroy hydrazine sulfate. Penthouse, September 1998.
64. U.S. General Accounting Office. Contrary to allegation, NIH hydrazine sulfate studies were not flawed. GAO/HEHS-95-141, September 13, 1995.
65. Julien, R.M. A Primer of Drug Action. W.H. Freeman Co.: New York , 1995.
66. Tice, B.D. Letter to Dr. Robert M. Julien, M.D., Ph.D., March 21, 1966.
67. Julien R.M. Letter to Barry D. Tice, April 26, 1996.
68. National Cancer Institute. Hydrazine sulfate. PDQ Complementary/Alternative Medicine, October 25, 1999 .
69. U.S. Food and Drug Administration. Transcript, meeting of Pharmacy Compounding Advisory Committee, Rockville , Maryland , May 7, 1999.
70. Pfeiffer, N. High doses of Megastrol stimulate appetite, weight gain. Oncology Times 12:1, December 1990.
71. Loprinzi, C.L. Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and North Central Cancer Treatment Group, sem. Oncol. 17(6), Supplement 9:8-12, 1990.
72. Ehrle, L.H. Letter to Randy P. Juhl, Chair, FDA Pharmacy Compounding Advisory Committee, November 3, 1999.
73. Hainer, M.I., Tsai, N., Komura, S.T. and Chiu, C.L. Fatal hepatorenal failure associated with hydrazine sulfate. Ann. Int. Med. 135:877-880, 2000.
74. Black, W. and Hussain, H. Hydrazine sulfate, the internet, isoniazid and the liver. Ann. Int. Med. 135:911-912, 2000.
75. Chlebowski, R.T., Grosvenor, M., Bernard, N., et al. Alteration in nutritional status, gastrointestinal symptoms and clinical outcome in AIDS. Proc. Am. Soc. Clin. Oncol. 7:4, 1988.
76. Gold, J. More about: biology of cachexia. J. Natl. Cancer Inst. 90:1101, 1998.
77. Abelson, R. Drug sales bring huge profits, and scrutiny, to cancer doctors. The New York Times, Sunday, January 26, 2003 , p. Al.
78. Filov, V.A., Gershanovich, M.L., Danova, L.A. and Ivin, B.A. Experience of the treatment with Sehydrin (hydrazine sulfate) in the advanced cancer patients. Invest. New Drugs 13:89-97, 1995.
J. Marvin Herndon, Ph.D.,“The Corruption of Science in America” http://www.thedotconnector.org/mag/index.php...
The above references are just a few, of many, which could be provided to dispute the misleading propaganda about our federal government agencies and science today by professor Mark Farmer in his article today in the Athens Banner Herald: http://onlineathens.com/opinion/2011-10-18/fa... Many more could be provided. In fact one could write a book on the subject of corruption in U.S. government agencies and indeed that is what some of the above references are all about.
I wouldn’t expect professor Farmer to criticize any government agency since he might fear losing some government grant money if he did. This illustrates the conflict of interest when government funds so called “scientific research”. Money and power get in the way of the truth. Remember when science was done without government funding? Remember all the great discoveries made then?
Why no great discoveries in say cancer today, after squandering over $100 billion on cancer research for the past nearly half century? The answer is corruption of science by government money. The cancer generals obviously don’t know what they are doing and continue to commit
#6 Mar 23, 2014
The cancer generals obviously don’t know what they are doing and continue to commit scientific misconduct, fraud, medical quackery and crimes against humanity while the unwitting public and idiots in Congress continue to throw hard earned public tax money at these corrupt idiots who have failed now for so long and killed so many unwitting cancer victims.
Finally, remember this: UGA constantly brags that it is the oldest public university in the country. So why is it they don’t have nor have had a single Nobel prize winner on the faculty either for work done here or elsewhere? I think professor Farmer should take his head out of the sand and not only stop trying to fool a gullible local population which is easily fooled, but stop trying to fool himself too as professor Feynman admonished.
Remember, this newspaper is an expert at seeking to fool readers. Over ten years ago the editors held me to strictly 500 words in an article opposing the American Cancer Society, while they published over 11,000 words plus three picture pages promoting it! These editors are experts at propaganda. They give space to professor Farmer while allowing anonymous cowards to make mostly irresponsible, meaningless comments about others with the protection of virtual white hoods over their heads provided by these editors, for the sole benefit of profit for this sorry excuse of a newspaper. The good citizens of Athens, Georgia evidently love to be fooled by the likes of this trash sheet the Athens Banner Herald which recently was kept afloat by a bankruptcy proceeding. While not all government workers and scientists are corrupt, tragically, many are, but one wouldn’t know it by reading the unenlightening Polly Anna comments by professor Farmer today. All this corruption is another unintended consequence of big government, big power and big money. The pharmaceutical and food processing companies have corrupted the U.S. FDA. They have so much money they can buy anyone, anything and any government. The U.S. FDA is a corrupt cesspool.
1. Who was Polly Anna?“ noun. an excessively or persistently optimistic person. Origin: name of the young heroine of novels by Eleanor H. Porter (1868-1920), U.S. writer
Winfield J. Abbe
A.B., Physics, UC Berkeley, 1961
M.S., Physics, California State University at Los Angeles, 1962
Ph.D., Physics, UC Riverside, 1966
Institute of Science and Technology Fellow, University of Michigan, Ann Arbor
Former faculty member at UGA with lifetime tenure.
Awards for outstanding achievement in mathematics, physics and chemistry.
Worked in theoretical elementary particle physics and experimental low temperature solid state physics.
Born at Cleveland, Ohio, raised at Sierra Madre, California.
“Cancer and Vitamin C Therapy for Patients”, Reagan Houston, Townsend Letter, Aug./Sept., 2007.
“Synergistic Killing of Ehrlich Ascites Carcinoma Cells by Ascorbate and 3-Amino-1,2,4, triazole” by Dean Burk, et al, Oncology 23: 33-43, 1969.
“The Hidden Story of Cancer” by Brian Peskin, Pinnacle Press, Houston, 2006-2010.
“The Search for Selective Biochemical Inhibotors” by E.J. Hoffman, CRC Press, Boca Raton, 2nd Ed.,
“Cancer-Gate” by Samuel S. Epstein, M.D., W. W. Norton, 2005.
“The Politics of Cancer Revisited” by Samuel S. Epstein, East Ridge Press, NY, 1998, 800 pages, 1200 references.
“The Cancer Industry” by Ralph W. Moss, Ph.D., Equinox Press, NY, 1996, 1989 and “The Cancer Syndrome”, 1980, 500 pages, 500 references.
“An Unsuccessful Effort to Deny Use of State of Georgia Facilities for fund raising by the American Cancer Society” by Winfield J. Abbe, Ph.D., May, 2000, UGa and Athens public libraries.
Add your comments below
|Relocating to Athens||Nov 19||Cece_Johnson||1|
|ort is the wrong party in court||Nov 11||wjabbe||4|
|Doppelgangers in America..||Nov 4||Typically Susanna||1|
|Charlie Hannah Augusta Board of Education Membe...||Nov 4||Typically Susanna||2|
|Bicentennial Celebration of the Birth of Crawfo...||Oct 29||wjabbe||2|
|mayors race in Nicholson||Oct '15||just wonder||1|
|Dopplegangers in Athens||Oct '15||Wadi||1|
Find what you want!
Search Athens Forum Now
Copyright © 2015 Topix LLC